Experimental Assessment of HOPO in Carbodiimide-Mediated Amide Coupling: Low-Racemization Control, Application Scenarios, and Process Considerations

Introduction

2-Hydroxypyridine N-oxide (2-hydroxypyridine N-oxide, HOPO) is commonly referred to simply as HOPO. In published pharmaceutical process case studies, it can be found in amide coupling conditions used in combination with carbodiimides such as EDCI, especially in steps where racemization control, late-stage coupling success, and process controllability must all be considered simultaneously. This use is illustrated by Ho’s 1995 report on biphasic carbodiimide coupling, Pfizer’s patents related to nirmatrelvir, the ubrogepant process, and the development literature on lufotrelvir. HOPO may be prioritized for screening in substrates prone to racemization and in critical late-stage couplings, with the key question being whether it can simultaneously improve stereochemical purity, reaction completion, and process controllability.

1. The Common Role of HOPO in Pharmaceutical Amide Coupling

In published pharmaceutical process patents, development papers, and reviews, HOPO typically appears in carbodiimide-mediated amide coupling systems as an auxiliary nucleophilic additive used in combination with EDCI or DCC. The available literature shows that the outcome of such couplings often depends on the overall combination of activator, additive, base, and solvent.

HOPO commonly appears in more demanding coupling steps, especially in situations where racemization at an α-stereogenic center must be controlled, late-stage fragment coupling must proceed smoothly, impurity levels must be suppressed, and scale-up reproducibility must also be maintained. Whether HOPO should be used generally needs to be judged within the context of the entire reaction system.

1.1 Representative References and Experimental Implications for HOPO in Pharmaceutical Amide Coupling

Source	Implications for experimental selection
Ho 1995	In biphasic carbodiimide coupling, HOPO was associated with high yield and low racemization, suggesting that it is suitable for inclusion in screening conditions for low-racemization coupling.
Pfizer patents related to nirmatrelvir	HOPO is listed as an auxiliary nucleophilic additive that can be used in combination with EDCI or DCC, and it also appears in specific coupling examples, indicating that it has been incorporated into the range of condition choices for key pharmaceutical coupling steps.
Ubrogepant process	Catalytic HOPO was used together with EDC, with the main purpose of reducing epimerization at the newly formed α-stereogenic center.
Lufotrelvir development	The use of HOPO needs to be evaluated together with solvent and activator; combinations of methyl ethyl ketone or acetone with EDCI/HOPO can affect epimerization control.
Magano review	The assessment of large-scale amidation should be based on the overall combination of activator, additive, base, and solvent.

2. Experimental Tasks for Which HOPO Is Suitable for Screening

In amide coupling, HOPO is more suitable for three types of tasks.

1. Substrates sensitive to racemization or epimerization at an α-stereogenic center. For such reactions, stereochemical purity, levels of related isomers, and yield should be compared as key parameters.

2. Critical late-stage fragment couplings, especially steps involving many functional groups and stringent impurity-control requirements. In these cases, in addition to reaction completion, the impurity profile and the difficulty of work-up should also be evaluated.

3. Routes that have already entered process development. For these tasks, in addition to the reaction itself, residual control, scale-up reproducibility, and the feasibility of raw material supply must also be considered simultaneously.

HOPO is more commonly used in screening conditions for amide coupling involving racemization-prone substrates, critical late-stage couplings, and process-demanding applications. For routine amidations with insensitive substrates and only moderate coupling difficulty, whether HOPO should be used should be determined on the basis of comparative experimental results. When the route places greater emphasis on operational simplicity, analytical burden, and supply maturity, HOPO usually does not need to be treated as the preferred option.

2.1 Experimental Tasks for Which HOPO Should Be Prioritized in Screening and Key Evaluation Points

Experimental task	Should HOPO be prioritized for screening?	Key points to monitor during screening
Amide coupling with α-stereogenic centers prone to racemization or epimerization	Yes	Stereochemical purity, related isomers, yield
Critical late-stage fragment coupling with functionally dense substrates	Yes	Reaction completion, impurity profile, work-up difficulty
Process-development stage requiring both scale-up and quality control	Yes	Residual control, batch consistency, manufacturability of raw materials
Routine amidation with insensitive substrates	Not necessarily as a default priority	Simplicity, cost, analytical burden
Development primarily aimed at the lowest cost and the simplest method	Usually not a priority option	Overall cost, analytical method workload, supply stability

3. Process Control Points That Require Parallel Attention When HOPO Is Used

Once HOPO has been incorporated into coupling conditions, process evaluation should not focus only on yield and racemization control. It should also establish controls in three areas: residual analysis, genotoxicity-related concerns, and raw material manufacturability. Published studies have reported analytical methods for trace HOPO in pharmaceutical-relevant materials, research findings on the genotoxicological profile of HOPO, and its continuous-flow synthesis and scale-up process.

Process control point	Why it requires attention	What should be done in parallel during process development
Residual analysis	Analytical methods for trace detection of HOPO in pharmaceutical-relevant materials have already been reported, indicating that once it enters a process, it should be included in residual control	Establish an HOPO residual assay at an early stage, and evaluate control limits in conjunction with intermediates, final products, and cleaning validation
Genotoxicity-related concerns	Public studies have discussed positive/equivocal Ames results for HOPO, while subsequent re-evaluation and in vivo studies did not indicate in vivo genotoxicity	It should not be simply classified as either “safe” or “unsafe”; rather, it should be treated as a process-related impurity with corresponding analytical, assessment, and control strategies
Raw material manufacturability	Continuous-flow preparation and scale-up of HOPO have already been reported, providing one public basis for evaluating its raw material sourcing, batch consistency, and manufacturing scalability	When HOPO is used in critical late-stage couplings, evaluate raw material sourcing, batch consistency, and scale-up manufacturing routes in parallel

4. Product Navigation Table for HOPO Coupling Condition Screening and Process Applications (Choose Table 1 to Table 3 by Research or Experimental Objective)

Research or experimental objective	Recommended table to consult first	Why this table is prioritized	Suggested related table to consult	Navigation guidance
To understand the core composition of the HOPO coupling system and distinguish the roles of additives, carbodiimides, bases, and solvents	Table 1	Table 1 brings together HOPO, EDCI, DIC, DCC, DIPEA, methyl ethyl ketone, acetone, and key condition components such as Oxyma, HOAt, and HOBt	Then Table 2	Suitable for first establishing the condition framework of the HOPO/carbodiimide coupling system, then comparing low-racemization additives with traditional additives
To screen amide coupling conditions sensitive to racemization or epimerization and compare the performance of HOPO with other additives	Table 1	Table 1 contains HOPO, Oxyma, HOAt, HOBt, and different carbodiimides in the same place, making it convenient to set up direct parallel comparison conditions	Then Table 2	Suitable for first defining additive/activator combinations, then comparing differences in safety form and scale-up management for traditional additives
To compare the differences among EDCI, DIC, and DCC when paired with HOPO and determine which activation system is better suited to a substrate	Table 1	Table 1 places the three carbodiimides and the HOPO system in one table, making it convenient to compare activation mode, by-product state, work-up, and substrate compatibility	Then Table 3	Suitable for first selecting the activator, then combining that information with published case studies to judge which systems are more suitable for critical late-stage couplings or complex pharmaceutical processes
If HOBt or HOAt conditions are already in hand and one wishes to evaluate whether to switch to HOPO or Oxyma while also considering safety form and substitution feasibility	Table 2	Table 2 focuses on comparison forms such as HOBt monohydrate, making it more suitable for first judging differences among traditional additives in storage, transport, weighing, and scale-up management	Then Table 1	Suitable for first examining the safety forms of traditional systems, then comparing the application choices of HOPO, Oxyma, and HOAt in coupling conditions
To screen the influence of solvents such as methyl ethyl ketone and acetone on HOPO coupling outcomes, and determine whether the solvent changes racemization, conversion, or work-up performance	Table 1	Table 1 places the key solvents used in the HOPO system together with the core coupling components, making it convenient to perform condition screening centered on the solvent variable	Then Table 3	Suitable for first comparing solvent/condition combinations, then using the lufotrelvir case to understand the role of solvent selection in published processes
To start from published pharmaceutical process cases and understand the application scenarios of HOPO in critical late-stage couplings	Table 3	Table 3 brings together case molecules such as nirmatrelvir, ubrogepant, and lufotrelvir, making it more suitable for mapping the application position of HOPO in real pharmaceutical processes	Then Table 1	Suitable for first examining actual application scenarios of HOPO, then looking back at the related combinations of additives, activators, bases, and solvents
To extend HOPO research from coupling applications to upstream preparation, oxidation routes, and continuous-flow scale-up	Table 3	Table 3 includes 2-hydroxypyridine and hydrogen peroxide, allowing the discussion of HOPO to be extended to preparation and scale-up	Then Table 1	Suitable for first examining the preparation and scale-up route of HOPO, then returning to the coupling system to understand its process-integration significance
If the current task is late-stage fragment coupling with functionally dense substrates, and both stereochemical retention, reaction completion, and work-up need to be considered	Table 1	Table 1 is the most suitable place to first establish screening combinations of HOPO/carbodiimide/base/solvent, directly corresponding to the common variables in critical late-stage coupling	Then Table 3	Suitable for first completing the screening of condition combinations, then referring to published cases to judge which combinations are closer to the needs of complex substrates and late-stage process development

Table 1 | Core HOPO/Carbodiimide Coupling System and Key Solvents

Category	CAS No.	Aladdin Catalog No.	Name	Grade or Purity	Product Features and Applications
Key coupling solvent	78-93-3	B1506362	2-Butanone	For HPLC, ≥99.7%	Used as a key screening solvent in published HOPO/EDCI coupling cases, balancing substrate solubility, reaction mass transfer, and work-up convenience; suitable for screening epimerization control in late-stage amide coupling.
Supporting organic base	7087-68-5	D109322	N,N-Diisopropylethylamine	Redistilled grade, ≥99.5%	Commonly used as the acid scavenger base and deprotonation component in HOPO/carbodiimide systems. Suitable for use with HOPO and EDCI to assess reaction completion, stereochemical retention, and work-up differences arising from salt byproducts.
Key coupling solvent	67-64-1	A399724	Acetone	ACS, ≥99.5%	Can serve as an important screening solvent for HOPO/EDCI conditions and is suitable for comparing the effects of different carbonyl-containing solvents on coupling rate, epimerization, and crystallization-based purification performance.
High-activity reference additive	39968-33-7	H109328	1-Hydroxy-7-azabenzotriazole	≥99%	Commonly used as a high-activity, low-racemization reference additive. Suitable for parallel comparison with HOPO in coupling of sterically hindered or chiral substrates, with emphasis on differences in reaction efficiency, racemization level, and impurity profile.
Classical low-racemization reference additive	2592-95-2	H684271	1-Hydroxybenzotriazole (HOBt)	≥99%	A classical additive used with carbodiimides and suitable as a low-racemization coupling reference against HOPO. It can also be used to evaluate the additional burden of traditional routes in thermal safety, residual control, and scale-up management.
Classical carbodiimide activator	538-75-0	D106074	N,N′-Dicyclohexylcarbodiimide	≥99%	A traditional carboxylic acid activator, suitable for establishing a classical coupling reference when used with HOPO or HOBt-type additives. Its urea byproduct is insoluble, making it useful for comparing different activators in filtration-based impurity removal and work-up complexity.
Soluble carbodiimide activator	693-13-0	N420184	N,N′-Diisopropylcarbodiimide	≥98.5%	Commonly used in amide coupling screening with additives such as HOPO, Oxyma, and HOBt. Suitable for evaluating activation efficiency and racemization control with sterically hindered substrates, chiral substrates, and different solvent conditions.
Core carbodiimide activator	25952-53-8	E106172	N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride	≥98%	A core water-soluble carbodiimide activator, suitable for low-racemization amide coupling condition screening in combination with HOPO, DIPEA, and MEK/acetone, with emphasis on comparing conversion, epimerization, and work-up convenience.
Core coupling additive	13161-30-3	P103097	2-Pyridinol N-oxide	≥98%	A typical nucleophilic additive used with carbodiimides, suitable for racemization-sensitive amide bond formation, late-stage fragment coupling, and optimization of conditions for complex substrates, with emphasis on ee/dr, impurity profile, and scale-up consistency.
Low-racemization reference additive	3849-21-6	E138773	Ethyl (hydroxyimino)cyanoacetate	≥98%	An Oxyma-type additive, suitable for parallel comparison with HOPO, HOAt, and HOBt in terms of low-racemization performance, reaction rate, and safety-management differences. It is an important reference when screening carbodiimide coupling additives.

Table 2 | Low-Racemization Reference Additives and HOBt Hydrated Safer-Form Reference Additives

Category	CAS No.	Aladdin Catalog No.	Name	Grade or Purity	Product Features and Applications
HOBt hydrated safer-form reference additive	80029-43-2	H157386	1-Hydroxybenzotriazole Monohydrate	≥97%(T)	Suitable for parallel comparison with anhydrous HOBt, HOPO, and Oxyma, with emphasis on the effects of the hydrated form on weighing correction, storage and transport management, and process operability.
HOBt hydrated safer-form reference additive	123333-53-9	H106176	1-Hydroxybenzotriazole Monohydrate	≥97%	Suitable for establishing comparison conditions for the hydrated form of HOBt, comparing its application differences versus HOPO, Oxyma, and HOAt in low-racemization coupling screening, while also paying attention to water content and thermal hazard management during scale-up operations.

Table 3 | Reagents for Upstream HOPO Preparation and Molecules from Published Pharmaceutical Process Case Studies

Category	CAS No.	Aladdin Catalog No.	Name	Grade or Purity	Product Features and Applications
Upstream oxidant for HOPO preparation	7722-84-1	H112520	Hydrogen peroxide solution	PharmPure™, USP, BP, European Pharmacopoeia (Ph.Eur), 30-31%	Can be used in upstream studies on the oxidation of 2-hydroxypyridine to prepare HOPO, with emphasis on oxidation efficiency, exotherm control, quench handling, and continuous-flow scale-up conditions.
Molecule from published pharmaceutical process case studies	2628280-40-8	P406646	PF-07321332	Moligand™, ≥99%	This is nirmatrelvir, which can serve as a case-study molecule from Pfizer-related patents for revisiting the coordinated selection of HOPO with activator, base, and solvent under carbodiimide coupling conditions.
Molecule from published pharmaceutical process case studies	2468015-78-1	L406648	Lufotrelvir (PF-07304814)	Moligand™, ≥96%	Published development literature indicates that EDCI/HOPO in combination with methyl ethyl ketone or acetone is critical for reducing epimerization, making this a representative case for linked optimization of solvent and coupling conditions.
Molecule from published pharmaceutical process case studies	1374248-77-7	U614612	ubrogepant	Moligand™	In the published process, the final coupling used EDC together with catalytic HOPO to control epimerization, making it suitable for understanding the application of HOPO in late-stage chiral amide coupling.
Upstream starting material for HOPO preparation	142-08-5	H108693	2-Hydroxypyridine	≥97%	The direct upstream starting material for HOPO, suitable for N-oxidation preparation studies in combination with hydrogen peroxide, with emphasis on oxidation selectivity, process integration, and scale-up conditions.

Note: The above are representative Aladdin products. For more product specifications, please refer to the product list at the end of the article, or search the Aladdin website using the product name, CAS number, or catalog number.

References

[1] Ho GJ, Emerson KM, Mathre DJ, Shuman RF, Grabowski EJJ. Carbodiimide-Mediated Amide Formation in a Two-Phase System. A High-Yield and Low-Racemization Procedure for Peptide Synthesis. J Org Chem. 1995;60(11):3569-3570. doi:10.1021/jo00116a057.

[2] Pfizer Inc. Nitrile-Containing Antiviral Compounds. WO2021250648A1. 2021.

[3] Yasuda N, Cleator E, Kosjek B, et al. Practical Asymmetric Synthesis of a Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist Ubrogepant. Org Process Res Dev. 2017;21(11):1851-1858. doi:10.1021/acs.oprd.7b00293.

[4] Allais C, Bernhardson D, Brown AR, et al. Early Clinical Development of Lufotrelvir as a Potential Therapy for COVID-19. Org Process Res Dev. 2023;27(12):2223-2239. doi:10.1021/acs.oprd.2c00375.

[5] Magano J. Large-Scale Amidations in Process Chemistry: Practical Considerations for Reagent Selection and Reaction Execution. Org Process Res Dev. 2022;26(6):1562-1689. doi:10.1021/acs.oprd.2c00005.

[6] Denton JR, Thomas S, Mao B. General Approach for the Chromatographic Determination of 2-Hydroxypyridine-1-oxide (HOPO) in Pharmaceutically Relevant Materials Utilizing a High pH Ion-Pairing Strategy. J Pharm Biomed Anal. 2015;115:62-68. doi:10.1016/j.jpba.2015.05.037.

[7] Dobo KL, Cheung JR, Gunther WC, Kenyon MO. 2-Hydroxypyridine-N-oxide (HOPO): Equivocal in the Ames Assay. Environ Mol Mutagen. 2018;59(4):312-321. doi:10.1002/em.22179.

[8] Dobo KL, Coffing S, Gunther WC, Homiski M. 2-Hydroxypyridine N-Oxide Is Not Genotoxic in Vivo. Environ Mol Mutagen. 2019;60(7):588-593. doi:10.1002/em.22294.

[9] Subirós-Funosas R, Prohens R, Barbas R, El-Faham A, Albericio F. Oxyma: An Efficient Additive for Peptide Synthesis to Replace the Benzotriazole-Based HOBt and HOAt with a Lower Risk of Explosion. Chem Eur J. 2009;15(37):9394-9403. doi:10.1002/chem.200900614.

[10] Tao J, Li H, Zuo J, et al. Development and Scale-Up of a Fully Continuous Flow Synthesis of 2-Hydroxypyridine-N-oxide. Org Process Res Dev. 2024;28(5):1640-1647. doi:10.1021/acs.oprd.3c00285.

[11] Wehrstedt KD, Wandrey PA, Heitkamp D. Explosive Properties of 1-Hydroxybenzotriazoles. J Hazard Mater. 2005;126(1-3):1-7. doi:10.1016/j.jhazmat.2005.05.044.

For more related articles, please see below:

The Methodological Value of Boc-Oxyma: Low-Racemization Coupling, Route Continuity, and Extended Applications

From “High Yield” to “Configuration Retention”: Activation-Stage Risks, Route Differences, and Selection Principles for Coupling Systems

The Methodological Value of HATU in Difficult Couplings: Reactivity Advantages, Stereochemical Retention, and Condition Management

Low-Racemization Control in Peptide Synthesis: An Inverse N→C Peptide Synthesis Strategy via Activated α-Aminoesters

Understanding ATD-DMAP: From Reagent Design to Esterification, Amidation, and Stereochemical Integrity